Chronic kidney disease (CKD) in children is a serious health challenge that often leads to dire consequences like high blood pressure, stunted growth, and eventually the need for life-saving interventions such as dialysis or kidney transplantation. But here's where it gets controversial—while existing treatments, including angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), have helped slow down the progression, many young patients still suffer from persistent proteinuria, a key indicator of ongoing kidney damage and a predictor of worsening disease. This leaves a critical question unanswered: how can we better protect these vulnerable children?
At the American Society of Nephrology Kidney Week 2025, Dr. Pinaki Mukhopadhyay, MBBS, MD, introduced the FIONA study, a pioneering clinical trial aimed at addressing this very issue. The study investigates finerenone, a novel therapeutic agent, to see if it can safely and effectively reduce proteinuria when used alongside standard treatments like ACE inhibitors or ARBs in children with CKD. FIONA is not just any trial—it is a carefully designed, multicenter, randomized, placebo-controlled study spanning six months.
What sets FIONA apart is its tailored approach: the dose of finerenone is precisely adjusted based on the child’s age and body weight to optimize treatment outcomes. Conducted at Nil Ratan Sircar Medical College and Hospital in Kolkata, West Bengal, India, this study is breaking new ground by focusing specifically on pediatric patients—a group underserved by many clinical trials that typically center on adults.
And this is the part most people miss: proteinuria doesn’t just signal kidney damage; it actively contributes to disease progression. So, if finerenone proves effective in reducing proteinuria further than current therapies, it could dramatically change the outlook for children with CKD, possibly delaying or even preventing the need for dialysis or transplant.
But here’s a debate starter—will adding another medication complicate treatment adherence or introduce unforeseen risks in children who already deal with complex regimens? The FIONA study’s detailed evaluation of safety, along with pharmacokinetics and pharmacodynamics, aims to answer these critical questions.
This trial represents hope and a potential turning point in pediatric nephrology, but it also challenges clinicians, families, and researchers to think critically about balancing innovation with caution. What do you think—could finerenone be the breakthrough pediatric CKD treatment we’ve been waiting for, or is it too early to tell? Share your thoughts and insights below!
